K. Annecke

Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy

R. Langer, M. Kiechle, N. Harbeck, 2009, Breast Cancer Research and Treatment.

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study

M. Kiechle, N. Harbeck, J. Huober, 2016, British Journal of Cancer.

Molecular risk estimation and adjuvant chemotherapy in node-negative breast cancer patients-A status report of the prospective clinical trial NNBC 3-Europe.

C. Meisner, N. Harbeck, C. Thomssen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer

M. Kiechle, K. Friese, W. Janni, 2012, Breast Care.

uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial.

N. Harbeck, G. von Minckwitz, C. Thomssen, 2008, Advances in clinical chemistry.

Sequential Treatment with Epirubicin/Cyclophosphamide, Followed by Docetaxel Is Equieffective, but Less Toxic Than FEC120 in the Adjuvant Treatment of Breast Cancer Patients with Extensive Lymph Node Involvement: The German ADEBAR Phase III Study.

M. Kiechle, N. Harbeck, H. Sommer, 2009 .

Differential expression of c‐Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue

J. Schäfer, J. Nährig, E. Lengyel, 2007, Histopathology.

Final toxicity analysis of the ADEBAR phase III study evaluating the role of docetaxel in the adjuvant therapy of breast cancer patients with extensive lymph node involvement

N. Harbeck, H. Sommer, K. Friese, 2007 .

Obesity and tumor characteristics in nodal-positive early-stage breast cancer: Results of the German ADEBAR study.

M. Kiechle, N. Harbeck, H. Sommer, 2010 .

Influence of sequencing of chemotherapy and radiotherapy regarding adverse effects of the cytostatic treatment: Results of the ADEBAR trial

N. Harbeck, H. Sommer, K. Friese, 2007 .